Oncology Med Executes Its Second Contract for Its New Prostate Cancer Brachytherapy Program With Ambulatory Surgery Center Locat
20 3월 2008 - 8:05PM
Marketwired
PITTSBURGH, PA announced that it has executed its second
contract for its new brachytherapy program with an ambulatory
surgical center located in the Northeast. Brachytherapy is the
treatment of prostate cancer through the implantation of
radioactive seeds. It is projected that the contract will add $
300,000.00 of revenue over the next 12 months thereby increasing
the Company's run rate by 15% over that same period.
Dr. William J. Walker, chairman of Oncology Med, Inc., stated,
"I am extremely pleased with the execution of our second contract
for our new prostate cancer brachytherapy program. As we mentioned
in our press release dated February 12, 2008, the new rules and
changes made to reimbursement policies for ambulatory surgical
centers by the Center for Medicare and Medicaid Services will
increase the demand for our services to these medical facilities.
This second contract is an additional endorsement of the tremendous
opportunity available to us and I believe there will be several
additional contracts we may enter into in the near future."
About Oncology Med, Inc.
Oncology Med is a public company engaged in the fulfillment of
services related to the treatment of various cancers. It currently
provides analysis and design of radiation treatment plans in order
for radiation oncologists to administer radiation plans to cancer
patients. Current services facilitate radiation treatment programs
ranging from external beam radiation to more advanced radiation
treatment technologies.
More information about Oncology Med, Inc. can be found at
www.oncologymed.com.
NOTE: This press release may contain "forward-looking
statements." In some cases, you can identify forward-looking
statements by terminology such as "may," "will," "should," "could,"
"expects," "plans," "intends," "anticipates," "believes,"
"estimates," "predicts," "potential," "continue" or the negative of
such terms and other comparable terminology. These forward-looking
statements include, without limitation, statements about our market
opportunity, our strategies, competition, expected activities and
expenditures as we pursue our business plan, and the adequacy of
our available cash resources. Although we believe that the
expectations reflected in any forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. Actual results may differ materially
from the predictions discussed in these forward-looking statements.
Changes in the circumstances upon which we base our predictions
and/or forward-looking statements could materially affect our
actual results.
For information, please contact: Oncology Med, Inc. Email
Contact
Bellatora (PK) (USOTC:ECGR)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Bellatora (PK) (USOTC:ECGR)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
